Erasca Q3 2024 net loss $31.2M; cash $463.3M; positive Phase 1b naporafenib data

Erasca, Inc.

2024-Q3 EPS reported -$0.60

Net loss of $31.2M ($0.11/share) vs $30.4M ($0.20/share) in Q3 2023.
Cash, equivalents, and marketable securities $463.3M; expected to fund operations into H1 2027.
R&D expenses $27.6M (up from $25.2M YoY) driven by clinical and preclinical activities.
Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib + trametinib in NRASm melanoma bolsters Phase 3 SEACRAFT-2 conviction.
IND filings on track: ERAS-4001 pan-KRAS inhibitor Q1 2025, ERAS-0015 pan-RAS glue H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.